The biopharma industry is increasingly focused on the weight loss sector, projected to surpass $130 billion by 2035. Analysts anticipate significant developments in the oral market and novel mechanisms as 2026 approaches.
Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of slowing down as analysts gear up for a year that will test the oral market and provide key data on novel mechanisms.
Original title: “Obesity Space Abuzz With Oral, Amylin Assets as Momentum Rides Into 2026”